Trending...
- Actress/Model Raelia Lewis Building a Powerful Name in Entertainment and Fashion
- Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals
- Bethany Nikitenko Elected Board Vice President of Philadelphia VIP
PHILADELPHIA, Nov. 9, 2023 ~ Suvoda LLC, a leading global clinical trial technology company, has successfully conducted usability testing of its electronic clinical outcomes assessment (eCOA) solution in collaboration with RWS Life Sciences. The study resulted in the certification of Suvoda eCOA as highly usable and effective for the patient population.
The findings from the RWS Life Sciences usability testing effort will be presented in a paper titled "Solidifying Usability Testing Guidelines for eCOAs from the Patient Perspective" at ISPOR Europe 2023, to be held in Copenhagen, Denmark, November 12-15. The focus group consisted of oncology patients using smartphone and tablet devices. These patients represented a variety of conditions related to their cancer diagnoses, including difficulties with gripping and reading, as well as concentration and tactile challenges. The study, which included participants ranging from ages 18 to 75, was qualitative in nature and adhered to best practices in user experience research.
More on The PennZone
Chryso Hadjidemetriou, PhD with RWS Life Sciences said "Patient-centered usability testing is valuable because it focuses on whether patients can interact with the eCOA efficiently and effectively, particularly in cases where participants may experience physical or visual accessibility challenges." He further added that "The qualitative and patient-centered process of usability testing helps to measure operational efficacy of the eCOA system; recognize design issues causing patient dissatisfaction and impeding data collection; examine software and working improvements; and understand and evaluate user interaction, with an end-goal of improving the users' experience."
Nearly all participants in the focus group found Suvoda eCOA to be easy to navigate, intuitive, clear, and well-designed. They appreciated the ease of moving through the questionnaire screens, clear instructions, and the flexibility to change answers as needed. Catherine Munera vice president of biometrics for Cara Therapeutics said "Patient-reported outcome (PRO) data is crucial in clinical studies so it's imperative to have data capture tools that are easy for patients to use and manage with minimal intervention from clinical sites." She further added that "Suvoda eCOA was incredibly easy for our patients to use; we had an increase in patient compliance in completing PRO questionnaires as compared to previous studies with other eCOA providers."
More on The PennZone
The usability testing process was conducted in accordance with current industry standards and FDA guidance to ensure the highest level of quality and compliance. Andrés Escallón vice president Suvoda eCOA practice said "Suvoda put the user experience at the center of product development so sites can focus time on patients and not on technology." He further added that "This study validates that our eCOA solution makes it easy and efficient to obtain quality patient outcomes data for submissions and approvals."
Suvoda announced general availability of its eCOA product back in May 2023 which addresses difficulties associated with traditional eCOA products by delivering simplified questionnaire licensing & localizations along with streamlined device logistics. Additionally since Suvoda's solution delivers IRT & Econsent on a single platform it helps improve data integrity & study teams benefit from improved data integrity.
The findings from the RWS Life Sciences usability testing effort will be presented in a paper titled "Solidifying Usability Testing Guidelines for eCOAs from the Patient Perspective" at ISPOR Europe 2023, to be held in Copenhagen, Denmark, November 12-15. The focus group consisted of oncology patients using smartphone and tablet devices. These patients represented a variety of conditions related to their cancer diagnoses, including difficulties with gripping and reading, as well as concentration and tactile challenges. The study, which included participants ranging from ages 18 to 75, was qualitative in nature and adhered to best practices in user experience research.
More on The PennZone
- Ashikaga Flower Park's "Great Wisteria Festival 2026"
- Washington County PA Real Estate is Changing Here's What Homeowners Need to Know Before Selling
- Architect of Neurodiversity Will Lead the First U.S. Team of Autistic Children to the "Genius Cup" in Hiroshima, Japan, in 2027
- Deborah E. Jones Introduces Emotional Sovereignty, a Powerful New Book on Emotional Mastery, Resilience, and Intentional Living
- New Research Identifies "The Busy Effect": 89% of Americans Want a Laid-Back Vacation — Only 15% Actually Achieve It
Chryso Hadjidemetriou, PhD with RWS Life Sciences said "Patient-centered usability testing is valuable because it focuses on whether patients can interact with the eCOA efficiently and effectively, particularly in cases where participants may experience physical or visual accessibility challenges." He further added that "The qualitative and patient-centered process of usability testing helps to measure operational efficacy of the eCOA system; recognize design issues causing patient dissatisfaction and impeding data collection; examine software and working improvements; and understand and evaluate user interaction, with an end-goal of improving the users' experience."
Nearly all participants in the focus group found Suvoda eCOA to be easy to navigate, intuitive, clear, and well-designed. They appreciated the ease of moving through the questionnaire screens, clear instructions, and the flexibility to change answers as needed. Catherine Munera vice president of biometrics for Cara Therapeutics said "Patient-reported outcome (PRO) data is crucial in clinical studies so it's imperative to have data capture tools that are easy for patients to use and manage with minimal intervention from clinical sites." She further added that "Suvoda eCOA was incredibly easy for our patients to use; we had an increase in patient compliance in completing PRO questionnaires as compared to previous studies with other eCOA providers."
More on The PennZone
- Alchemy 43 Appoints Shane Smith as CEO to Drive Operational Performance and Scalable Growth
- Best Spiritual Healing, Meditation & Retreats in Sedona — Rise Meditation Helps You Find and Book Transformational Experiences
- $16 Billion Market by 2034 in Underwater Drones Presents Huge Opportunity for AI-Powered Autonomous Vehicle Serving Defense & Commercial Customers
- Appliance EMT Named Among Jacksonville's Top 3 Appliance Repair Companies by ThreeBestRated®
- The Scratch-Off Dead Zone - is your state lottery failing?
The usability testing process was conducted in accordance with current industry standards and FDA guidance to ensure the highest level of quality and compliance. Andrés Escallón vice president Suvoda eCOA practice said "Suvoda put the user experience at the center of product development so sites can focus time on patients and not on technology." He further added that "This study validates that our eCOA solution makes it easy and efficient to obtain quality patient outcomes data for submissions and approvals."
Suvoda announced general availability of its eCOA product back in May 2023 which addresses difficulties associated with traditional eCOA products by delivering simplified questionnaire licensing & localizations along with streamlined device logistics. Additionally since Suvoda's solution delivers IRT & Econsent on a single platform it helps improve data integrity & study teams benefit from improved data integrity.
Filed Under: Business
0 Comments
Latest on The PennZone
- FinIQ Edu Launches High-Impact Workshop Vertical to Close the Workplace Benefits Gap—Drives 82% Surge in 401(k) Participation Intent
- HousingWire launches Mortgage Rankings, bringing a data-driven benchmark to originator performance
- J&J Exterminating Reminds Residents to prepare for Termite Swarm Season
- Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals
- Tyler G. Hicks' Encyclopedia of Wealth Building Secrets Released in a Powerful New Edition
- Just 1 in 57 Crypto Owners Globally Pay Taxes on Their Holdings, New Report Finds
- New Book Gives Technology Leaders the Blueprint to Drive Real, Lasting Impact
- IQSTEL accelerates toward profitability inflection with $317M revenue and AI-driven expansion; IQSTEL Inc. (N A S D A Q: IQST) i
- AI-Driven Breakthrough Unleashed: Bionic Intelligence Platform Goes Live to Capture Massive Biotech Opportunity: KALA BIO, Inc. (N A S D A Q: KALA)
- Surging Into Hyper-Growth Mode With Record Revenue, Raised 2026 Guidance, and Game-Changing AI Platform; Off The Hook YS (NYSE American: OTH)
- Mom Creators Coalition Launches with WaterWipes® as Official Founding Sponsor
- PandaGuarantee Launches Rent Guarantor Service in New York City
- The $112M Marketing Lesson Joe Whyte Learned: Why 'More Traffic' Is the Biggest Lie in Digital Marketing
- Daniel Kaufman Expands Kaufman & Company Real Estate Platform With New Acquisitions, AI-Driven Industrial Development and Nationwide Growth Initiative
- Bethany Nikitenko Elected Board Vice President of Philadelphia VIP
- purelyIV Launches Lab Testing Services in Metro Detroit
- On the 296th Anniversary of the Ceremony That Made His Ancestor Emperor, a Cherokee Descendant Publishes the Novel That Restores Him
- Burkentine Builders Breaks Ground on Their 100,000-Square-Foot Warehouse in Shippensburg, PA
- NRx Pharmaceuticals Could Be on the Verge of a Breakout Year as AI, FDA Catalysts, and Mental Health Demand Converge
- Pine Creek Rail Trail Named Pennsylvania's 2026 Trail of the Year